Should enzalutamide be given concurrently with Sip-T in castration-resistant metastatic prostate cancer?  

In the phase 3 trial of sip-T, enzalutamide was not available, and concurrent therapy with anti-androgens was not permitted. In fact, all patients were required to be progressing on ADT and prior therapies to be eligible, and additional anti-cancer therapy beyond the sip-T and concurrent ADT was not...

Enzalutamide was still in early development when Sip-T was approved. Currently there isn’t enough data in the randomized setting, to justify the use. It’s a fascinating clinical question, and hopefully during the next couple of years, more data will become available.